Elutia Share Price (NASDAQ: ELUT)

$2.29

▲

-0.04

(-1.72%)

Last updated on August 30, 2025 at 1:29 am IST

$₹

Check the interactive Elutia Stock chart to analyse performance

Elutia stock performance

as on August 30, 2025 at 1:29 am IST

Today's Low:$2.23
Today's High:$2.29
$2.29
2.62%
Downside
Day's Volatility :2.62%
Upside
0.0%
52 Weeks Low:$1.61
52 Weeks High:$5.12
$2.29
29.69%
Downside
52 Weeks Volatility :68.55%
Upside
55.27%

Elutia Stock Returns

Period	Elutia Inc	Index (Russel 2000)
3 Months	30.4%	0.0%
6 Months	-26.91%	0.0%
1 Year	-43.47%	0.0%
3 Years	61.22%	-4.1%

Elutia Inc Key Stats

Check Elutia key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$2.33
Open	$2.23
Today's High	$2.29
Today's Low	$2.23
Market Capitalization	$98.8M
Today's Volume	$12.1K
52 Week High	$5.12
52 Week Low	$1.61
Revenue TTM	$23.7M
EBITDA	$-19.1M
Earnings Per Share (EPS)	$-0.43
Profit Margin	-90.01%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	0.0%

Stock Returns calculator for Elutia Stock including INR - Dollar returns

The Elutia stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Return is the profit earned when the US dollar rises in value compared to the Indian rupee.

Investment Value

₹1,00,000

Elutia investment value today

Current value as on today

₹61,688

Returns

₹38,312

(-38.31%)

Returns from Elutia Stock

₹43,596 (-43.6%)

Dollar Returns*

₹5,284 (+5.28%)

Indian investors sentiment towards Elutia Stock

-37%

Period: Jul 31, 2025 to Aug 30, 2025. Change in 30 Days versus previous period

Search interest for Elutia Stock from India on INDmoney has decreased by -37% in the last 30 days, reflecting a downward trend in search activity.

Analyst Recommendation on Elutia Stock

Rating

Trend

Buy

87%Buy

12%Hold

0%Sell

Based on 8 Wall street analysts offering stock ratings for Elutia(by analysts ranked 0 to 5 stars)

Elutia Share Price Target

What analysts predicted

Upside of 183.84%

Target:

$6.50

Current:

$2.29

Elutia share price target is $6.50, a slight Upside of 183.84% compared to current price of $2.29 as per analysts' prediction.

Elutia Stock Insights

Price Movement
In the last 7 days, ELUT stock has moved up by 9.8%
Increasing Revenue
Revenue is up for the last 3 quarters, 5.46M → 6.26M (in $), with an average increase of 6.5% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, -3.93M → -9.61M (in $), with an average decrease of 144.3% per quarter
ELUT vs BSX (1 yr)
In the last 1 year, Boston Scientific Corp. has given 29.0% return, outperforming this stock by 73.0%
Price to Sales
ForELUT every $1 of sales, investors are willing to pay $3.6, whereas for Boston Scientific Corp., the investors are paying $8.4 for every $1 of sales.

Elutia Inc Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Revenue	$42.9M	↑ 9.9%
Net Income	$-11.9M	↑ 3.22%
Net Profit Margin	-27.83%	↑ 1.8%

	FY20	Y/Y Change
Revenue	$42.7M	↓ 0.51%
Net Income	$-21.8M	↑ 82.8%
Net Profit Margin	-51.13%	↓ 23.3%

	FY21	Y/Y Change
Revenue	$47.4M	↑ 11.03%
Net Income	$-24.8M	↑ 13.78%
Net Profit Margin	-52.4%	↓ 1.27%

	FY22	Y/Y Change
Revenue	$23.8M	↓ 49.68%
Net Income	$-32.9M	↑ 32.48%
Net Profit Margin	-137.94%	↓ 85.54%

	FY23	Y/Y Change
Revenue	$24.7M	↑ 3.76%
Net Income	$-37.7M	↑ 14.47%
Net Profit Margin	-152.18%	↓ 14.24%

	FY24	Y/Y Change
Revenue	$24.4M	↓ 1.5%
Net Income	$-53.9M	↑ 43.27%
Net Profit Margin	-221.33%	↓ 69.15%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Revenue	$6.7M	↑ 13.94%
Net Income	$-18.0M	↑ 93.19%
Net Profit Margin	-268.81%	↓ 110.27%

	Q2 FY24	Q/Q Change
Revenue	$6.3M	↓ 6.02%
Net Income	$-28.2M	↑ 56.61%
Net Profit Margin	-447.94%	↓ 179.13%

	Q3 FY24	Q/Q Change
Revenue	$5.9M	↓ 5.87%
Net Income	$1.3M	↓ 104.56%
Net Profit Margin	21.72%	↑ 469.66%

	Q4 FY24	Q/Q Change
Revenue	$5.5M	↓ 7.67%
Net Income	$-9.1M	↓ 804.59%
Net Profit Margin	-165.71%	↓ 187.43%

	Q1 FY25	Q/Q Change
Revenue	$6.0M	↑ 10.28%
Net Income	$-3.9M	↓ 56.59%
Net Profit Margin	-65.22%	↑ 100.49%

	Q2 FY25	Q/Q Change
Revenue	$6.3M	↑ 3.86%
Net Income	$-9.6M	↑ 144.34%
Net Profit Margin	-153.44%	↓ 88.22%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Profit	$19.8M	↑ 23.98%

	FY20	Y/Y Change
Profit	$20.6M	↑ 4.01%

	FY21	Y/Y Change
Profit	$19.0M	↓ 7.49%

	FY22	Y/Y Change
Profit	$11.6M	↓ 38.81%

	FY23	Y/Y Change
Profit	$11.1M	↓ 5.03%

	FY24	Y/Y Change
Profit	$10.7M	↓ 3.13%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Profit	$2.8M	↑ 33.85%

	Q2 FY24	Q/Q Change
Profit	$2.8M	↓ 1.55%

	Q3 FY24	Q/Q Change
Profit	$2.7M	↓ 2.07%

	Q4 FY24	Q/Q Change
Profit	$2.3M	↓ 15.21%

	Q1 FY25	Q/Q Change
Profit	$2.5M	↑ 5.72%

	Q2 FY25	Q/Q Change
Profit	$3.1M	↑ 24.46%

FY19

FY20

FY21

FY22

FY23

FY24

	FY19	Y/Y Change
Operating Cash Flow	$-8.4M	↑ 64.8%
Investing Cash Flow	$-577.0K	↑ 203.68%
Financing Cash Flow	$9.2M	↑ 31.64%

	FY20	Y/Y Change
Operating Cash Flow	$-13.4M	↑ 59.07%
Investing Cash Flow	$-640.0K	↑ 10.92%
Financing Cash Flow	$51.0M	↑ 454.53%

	FY21	Y/Y Change
Operating Cash Flow	$-15.6M	↑ 16.25%
Investing Cash Flow	$-369.0K	↓ 42.34%
Financing Cash Flow	$6.7M	↓ 86.85%

	FY22	Y/Y Change
Operating Cash Flow	$-21.4M	↑ 37.24%
Investing Cash Flow	$-540.0K	↑ 46.34%
Financing Cash Flow	$9.0M	↑ 34.15%

	FY23	Y/Y Change
Operating Cash Flow	$-21.8M	↑ 1.53%
Investing Cash Flow	$14.2M	↓ 2731.11%
Financing Cash Flow	$9.8M	↑ 9.3%

	FY24	Y/Y Change
Operating Cash Flow	$-22.7M	↑ 4.12%
Investing Cash Flow	$-474.0K	↓ 103.34%
Financing Cash Flow	$17.1M	↑ 73.72%

Q1 FY24

Q2 FY24

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

	Q1 FY24	Q/Q Change
Operating Cash Flow	$-2.6M	↓ 73.93%
Investing Cash Flow	$-15.0K	↓ 100.1%
Financing Cash Flow	$-4.1M	↓ 1249.44%

	Q2 FY24	Q/Q Change
Operating Cash Flow	$-4.3M	↑ 64.03%
Investing Cash Flow	$182.0K	↓ 1313.33%
Financing Cash Flow	$9.8M	↓ 340.53%

	Q3 FY24	Q/Q Change
Operating Cash Flow	$-3.4M	↓ 20.89%
Investing Cash Flow	$-547.0K	↓ 400.55%
Financing Cash Flow	$11.5M	↑ 17.78%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$-12.3M	↑ 257.66%
Investing Cash Flow	$-94.0K	↓ 82.82%
Financing Cash Flow	$-151.0K	↓ 101.31%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$-8.9M	↓ 27.54%
Investing Cash Flow	$-278.0K	↑ 195.74%
Financing Cash Flow	$13.3M	↓ 8893.38%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$-8.2M	↓ 7.35%
Investing Cash Flow	$-114.0K	↓ 58.99%
Financing Cash Flow	$-516.0K	↓ 103.89%

Elutia Technicals Summary

Sell

Neutral

Buy

Elutia is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Elutia Inc Vs Peers

Returns

Ratio's

Overview

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Elutia Inc	12.5%	-26.91%	-43.47%	61.22%	61.22%
Medtronic Plc	3.87%	-1.59%	4.32%	4.82%	-13.69%
Edwards Lifesciences Corp.	2.55%	13.95%	18.33%	-9.73%	-5.31%
Boston Scientific Corp.	0.09%	0.6%	30.02%	157.38%	154.4%
Stryker Corporation	3.63%	-0.85%	8.87%	89.43%	97.71%
Abbott Laboratories	4.24%	-5.37%	15.72%	26.56%	24.53%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Elutia Inc	NA	NA	NA	-0.6	0.0	-0.37	NA	-0.99
Medtronic Plc	25.4	25.4	2.14	5.46	0.1	0.05	0.03	37.36
Edwards Lifesciences Corp.	34.03	34.03	4.85	2.5	0.16	0.08	NA	17.94
Boston Scientific Corp.	62.95	62.95	1.84	2.98	0.12	0.05	NA	15.14
Stryker Corporation	51.54	51.54	2.24	13.49	0.14	0.08	0.01	55.43
Abbott Laboratories	16.64	16.64	4.17	5.14	0.31	0.07	0.02	29.05

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Elutia Inc	Buy	$98.8M	61.22%	NA	-90.01%
Medtronic Plc	Buy	$118.0B	-13.69%	25.4	13.63%
Edwards Lifesciences Corp.	Buy	$47.8B	-5.31%	34.03	72.96%
Boston Scientific Corp.	Buy	$156.7B	154.4%	62.95	13.55%
Stryker Corporation	Buy	$149.0B	97.71%	51.54	12.25%
Abbott Laboratories	Buy	$230.9B	24.53%	16.64	32.43%

About Elutia Inc

Elutia Inc., a commercial-stage company, develops and commercializes drug-eluting biologics products for neurostimulation and breast reconstruction in the United States. It operates in three segments: Device Protection, Women's Health, and Cardiovascular. The company offers EluPro, which is used to accommodate cardiac implantable electronic devices, such as pacemakers and internal defibrillators; and CanGaroo, which mitigates complications derived from implantable electronic devices and shortcomings of synthetic envelopes. It also provides ProxiCor for cardiac tissue repair and pericardial closure; Tyke, an extracellular material that is used in the repair of cardiac structures for neonate and infant patients; and VasCure, a patch material used to repair or reconstruct the peripheral vasculature. In addition, the company offers SimpliDerm, which uses human acellular dermal matrices for tissue repair and reconstruction in various applications, such as sports medicine, hernia repair, trauma reconstruction, and breast reconstruction. It serves hospitals and healthcare facilities through its direct sales force, commercial partners, independent sales agents, and distributors. The company was formerly known as Aziyo Biologics, Inc. and changed its name to Elutia Inc. in September 2023. Elutia Inc. was incorporated in 2015 and is headquartered in Silver Spring, Maryland.

Organization	Elutia
Employees	51
CEO	Dr. C. Randal Mills Ph.D.
Industry	Miscellaneous

Key Management of Elutia Inc

Name	Title
Dr. C. Randal Mills Ph.D.	Co-Founder, President, CEO & Director
Mr. Matthew B. Ferguson	Chief Financial Officer
Dr. Michelle LeRoux Williams Ph.D.	Chief Scientific Officer
Ms. Courtney Guyer	Vice President of Marketing
Dr. Sonali Fonseca Ph.D.	VP & Head of Emerging Businesses
Mr. Dwayne Montgomery	Head of Cardiovascular
Mr. Jeffry D. Hamet	Senior VP of Finance, Treasurer & Secretary

Important FAQs about investing in ELUT Stock from India :

What is Elutia share price today?

Elutia share price today is $2.29 as on August 30, 2025 at 1:29 am IST at the close of the market. Elutia share today touched a day high of $2.29 and a low of $2.23.

What is the 52 week high and 52 week low for Elutia share?

Elutia share touched a 52 week high of $5.12 and a 52 week low of $1.61. Elutia stock price today i.e. August 30, 2025 at 1:29 am IST is closed at $2.29, lower by 55.27% versus the 52 week high.

How to invest in Elutia Stock (ELUT) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Elutia on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Elutia Shares that will get you 0.6550 shares as per Elutia share price of $2.29 per share as on August 30, 2025 at 1:29 am IST.

What is the minimum amount required to buy Elutia Stock (ELUT) from India?

Indian investors can start investing in Elutia (ELUT) shares with as little as ₹88.286 or $1 (as of August 31, 2025) using the INDmoney app.
For example: If you want to invest $10 or ₹882.86 in Elutia stock (as per the Rupee-Dollar exchange rate as on August 31, 2025). Based on Elutia share’s latest price of $2.29 as on August 30, 2025 at 1:29 am IST, you will get 4.3668 shares of Elutia. Learn more about fractional shares .

What are the returns that Elutia has given to Indian investors in the last 5 years?

Elutia stock has given 61.22% share price returns and 20.51% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?